---
title: "Bezuclastinib in Nonadvanced systemic mastocytosis: Terms and abbreviations"
description: "Formulary evidence on Bezuclastinib in Nonadvanced systemic mastocytosis: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib in Nonadvanced systemic mastocytosis: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| ALT | Alanine aminotransferase |
| ANCOVA | Analysis of covariance |
| AST | Aspartate aminotransferase |
| BMD | Bone mineral density |
| BSC | Best supportive care |
| C7D1 | Cycle 7, day 1 |
| CI | Confidence interval |
| CNS | Central nervous system |
| CYP3A4 | Cytochrome P450 3A4 |
| EAP | Expanded access protocol |
| FDA | U.S. Food and Drug Administration |
| GIST | Gastrointestinal stromal tumor |
| Gr | Grade |
| H1 | Histamine H1 receptor |
| H2 | Histamine H2 receptor |
| ICC | Intraclass correlation coefficient |
| ICER | Incremental cost-effectiveness ratio |
| IgE | Immunoglobulin E |
| IQWiG | Institute for Quality and Efficiency in Health Care |
| ISM | Indolent systemic mastocytosis |
| ISM-SAF | Indolent Systemic Mastocytosis Symptom Assessment Form |
| ITT | Intention to treat |
| KIT | KIT receptor tyrosine kinase |
| MC | Mast cell |
| MC-QoL | Mastocytosis Quality of Life Questionnaire |
| MS2D2 | Mastocytosis Symptom Severity Daily Diary |
| NCCN | National Comprehensive Cancer Network |
| NDA | New Drug Application |
| NonAdvSM | Nonadvanced systemic mastocytosis |
| PBO | Placebo |
| PDUFA | Prescription Drug User Fee Act |
| PGIS | Patient Global Impression of Severity |
| Pts | Patients |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| SD | Standard deviation |
| SM | Systemic mastocytosis |
| SSM | Smoldering systemic mastocytosis |
| TKI | Tyrosine kinase inhibitor |
| TRAE | Treatment-related adverse event |
| TSS | Total symptom score |

## Related pages
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis.md)
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Product information and disease description](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Clinical evidence](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: References](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses.md)
